Sign In
Buy SGMO
$0.216
+0.0022 (+1.03%)
At Close: Jun 03, 2026
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025.
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check.
10:35am, Monday, 21'st Oct 2024
Sangamo Therapeutics, Inc.'s stock surged after positive updates on two lead assets, giro-vec and STAC-BBB, with potential for significant milestone payments and partnerships. The upcoming isa-vec dea
3 Penny Stocks To Buy With Just $750
10:36am, Tuesday, 24'th Sep 2024
Anyone with any experience as an investor knows that while penny stocks can produce strong returns, they're also risky.
Sangamo Therapeutics, Inc. (SGMO) Q2 2024 Earnings Call Transcript
07:07pm, Tuesday, 06'th Aug 2024
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communication
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
06:37pm, Tuesday, 06'th Aug 2024
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.37 per share a year ago.
Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today?
12:17pm, Tuesday, 06'th Aug 2024
Sangamo Therapeutics (NASDAQ: SGMO ) stock is rising higher on Tuesday after the clinical-stage genomic medicine company announced a new license agreement. Sangamo Therapeutics has signed a license ag
Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?
03:59pm, Wednesday, 24'th Jul 2024
When small-cap biotech stocks go on a tear, many investors pay attention. Little-known company Sangamo Therapeutics (NASDAQ: SGMO ) is making waves today, with SGMO stock up more than 40% at the time
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
12:10pm, Wednesday, 24'th Jul 2024
Sangamo Therapeutics Inc SGMO, which developed a treatment in collaboration with Pfizer Inc PFE, received a boost to its stock price after struggling with liquidity issues.
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
07:32pm, Tuesday, 23'rd Jul 2024
Sangamo Therapeutics, Inc. is almost out of cash, and as such, at risk of bankruptcy. Therefore, investing in this company is not a good idea for most investors. 3 of its assets have updates coming
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
07:32pm, Tuesday, 23'rd Jul 2024
Sangamo Therapeutics, Inc. is almost out of cash, and as such, at risk of bankruptcy. Therefore, investing in this company is not a good idea for most investors. 3 of its assets have updates coming
Sangamo Therapeutics, Inc. (SGMO) Q1 2024 Earnings Call Transcript
07:13pm, Thursday, 09'th May 2024
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications S
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
06:26pm, Thursday, 09'th May 2024
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to earnings of $0.12 per share a year ago.
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
04:15pm, Thursday, 02'nd May 2024
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast.
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Neurology Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at ASGCT.
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
08:05am, Friday, 22'nd Mar 2024
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES PRICING OF $24.0 MILLION REGISTERED DIRECT OFFERING.
